Indication

KRAS G12C Non-Small Cell Lung Cancer

Clinical and regulatory intelligence for KRAS G12C Non-Small Cell Lung Cancer with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Assets: 0

Relevant assets

No related entities indexed yet.

Relevant companies

Roche →

Recent signals(1)

ClinicalJuly 2, 2026

Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial

Upcoming catalysts

No catalysts indexed for this entity yet.

Therapeutic areas

KRAS G12C Non-Small Cell Lung Cancer →

Oncology →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.